



MINISTERIO
DE ECONOMÍA
Y COMPETITIVIDAD

isc
Instituto
de Salud
Carlos III



Fit for Health

Support to **SMEs & Researchers**
in **FP7 Health-oriented projects**

Related European programmes

5th September 2013 | Bucharest


Teresa Corral | Institute of Health Carlos III, Spain

www.fitforhealth.eu



Fit for Health is funded by
the European Commission


- Other EU R&D&I programmes
 - ✓ ERA-Nets
 - ✓ Joint Programming Initiatives (JPIs)
 - ✓ Art. 185 initiatives (e.g. AAL, EDCTP, Eurostars)
 - ✓ JTI: Innovative Medicine Initiative (IMI)
 - ✓ COST Actions
 - ✓ DG-SANCO



ERANET





ERANET +



JPIs


ARTs 185





- **EC** supports the **coordination costs**
- **Each national programme** supports **their national partners** within the selected projects

- NEURON II
- HIVERA
- Transcan
- E-Rare II (RO negotiation)
- Infect-ERA (1st call closed)
- EuroNanoMed II (call 2013 closed)
- Systems Biology (Early phase – 1st call November 2013)



Member States address global social problems - **great challenges:**

1. Identification of a common vision
2. Definition of Research Strategic Agenda
3. Implementation of RSA in a Joint Programming Initiative (JPI)


JPIs in Health:

Joint Programme Neurodegenerative Diseases Research

Joint Programming Initiative A healthy diet for a healthy life (RO)

Joint Programming Initiative More years better lives


Joint Programming Initiative on Antimicrobial Resistance (RO)



Other JPIs with Romanian participation:

- Agriculture, Food Security and Climate Change (FACCE)
- Healthy and productive seas and oceans (Oceans)
- Water challenges for a changing world (Water JPI)
- Cultural Heritage: A challenge for Europe (JHEP)





- Legal base: Article 185 of Lisbon Treaty
- Financial contribution from the European Commission and MS






Objectives:

- Enhance the quality of life of older people
- Strengthen the industrial base in Europe through the use of Information and Communication Technologies (ICT)


<http://www.aal-europe.eu/>

- 2008 – 2013
- 600 M€
- 300 M€:
 - 150 M€ to EU VII PM
 - 150 M€ to 23 MS of AAL




20 EU, 3 non EU
countries


Project partners in submitted proposals (N=1171)



Coordinators in submitted proposals



Organisation by type in submitted proposals (N=1171)



- The European commission has formally proposed a **continuation of the AAL Joint Programme** for the period 2014-2020
- **Aim:** support industry, in particular SME to bring digital innovative products and services for ageing well to the European market
- **Added value:** Alignment with the European Innovation Partnership on Active and Healthy Ageing (EIP AHA) could further boost deployment at European scale

- **Budget:** more than €700 million for 7 years



<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0500:FIN:en:PDF>



- **Aim:** Accelerate the development of new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa
- 16 European countries + 46 African countries
- 400 M€ (50% EU, 50% Africa)
- 326 projects funded with 312 M€

<http://www.edctp.org/>



- Applicants based at eligible institutions in sub-Saharan Africa or in European Member States (RO) may apply for EDCTP funding in compliance with call specific terms and conditions

- EDCTP will continue with ***EDCTP2 in 2014***, as part of Horizon 2020



<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0498:FIN:en:PDF>

- Dedicated to R&D performing SMEs
- SMEs to lead international collaborative research and innovation projects
- Support for market-driven research activities of SMEs
- At least 2 legal entities from 2 participating countries
- At least 50% of project core activities to be performed by SME(s)

<http://www.eurostars-eureka.eu>

- Bottom-up, but market-driven research
- Maximum duration: 3 years
- Within 2 years after completion, product should be ready for launch on market / clinical trials should start
- **Romania** is one of the current 33 countries actively participating in the Eurostars Programme through the EUREKA network of national offices

> Eurostars in ROMANIA

FUNDING BODY The Executive Unit for Financing Higher Education and Academic Research (UEFISCDI)
Dr. Eng. ALUPEI-COJOCARIU OVIDIU-DORIN
+40 753 102 025
ovidiu.alupei@uefiscdi.ro; ovidiu.alupei@gmail.com

more information / www.uefiscdi.ro

TYPE OF FUNDING /The applicant contractor must be a Company. Universities, Research Organisation, any other SME and/ or Large Company could be partners in the Romanian consortium.
Funding of the consortium members is made through the contractor company.

RULES

Type of organisation	Funding % of eligible costs	Maximum costs (in €)	Additional information
SME	35-80%, depending on the SME size and the activities type	depends on project type	with respect of the state aid scheme notified N542/2007 C2007(6545)
LARGE COMPANY	25-65%, depending on activities type	depends on project type	with respect of the state aid scheme notified N542/2007 C2007(6545)
UNIVERSITY	100%	depends on project type	The Romanian EUREKA Office recommends universities to apply together with a Romanian company
RESEARCH ORGANISATION	100%	depends on project type	The Romanian EUREKA Office recommends research organizations to apply together with a Romanian company
OTHER	100%	depends on project type	The Romanian EUREKA Office recommends to apply together with a Romanian company

ADDITIONAL INFORMATION

The priority order for funding is: EUROSARS projects, Cluster projects, EUREKA traditional projects, up to the limit of the yearly budget.
The limit of funding is up to 700,000 RON (~ 159,000€) / year for EUROSARS projects;

Romanian partners only will be funded by the NFB.

The contract procedure lasts between 3-6 months.

Categories and Project Research Types: Industrial (Applied) Research activities or Experimental Research activities.

Objectives:

- To promote market-oriented transnational research activities in any fields of research performing SMEs, leading to the placing of new or improved products, processes and services on the market
- To contribute to the completion of the ERA and to increase the accessibility, efficiency and efficacy of public funding for research-performing SMEs in Europe



<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0493:FIN:en:PDF>

- **Public-Private Partnership** between **EU** and **EFPIA** (European Federation of Pharmaceutical Industries and Associations)
- Budget: 2 billion € for 10 years (2008 – 2017; last call published in July 2013)



www.imi.europa.eu



- General aim: R&D to remove **delays** and **bottlenecks** in the drug development process
 - Efficacy of drugs
 - Safety of drugs
 - Knowledge Management
 - Education & Training
- **Romania** can participate in IMI
- Members of EFPIA, SMEs, Patients' organisations, Universities and other Research organisations, Hospitals, Regulatory agencies and any other industrial partners are eligible institutions





Innovative Medicines Initiative



Contact Newsletter Links

Search:

- Home
- About IMI
- Ongoing projects
- Calls for proposals
 - Call Overview - How to participate
 - Intellectual property policy
 - Future Topics
 - New opportunities
 - 9th Call 2013
 - Stage 1
 - 8th Call 2012
 - 7th Call 2012
 - 6th Call 2012
 - 5th Call 2012
 - 4th Call 2011
 - 3rd Call 2010
 - 2nd Call 2009
 - 1st Call 2008
- News, Events & Media
- Reference documents
- FAQ

IMI 9th Call 2013 - Stage 1

- New!** Questions & Answers on the 9th Call topics

On this page you find information necessary to submit an **Expression of Interest** in response to the IMI 9th Call 2013.

Based on the recommendations of the **IMI Research Agenda** the IMI Governing Board has approved the Scientific Priorities 2013 as part of **IMI Annual Implementation Plan 2013**.

Four of these priorities are implemented through the IMI 9th Call Topics (see Information Package below).

Applicants intending to submit an Expression of Interest (EoI) in response to the IMI 9th Call should read the Call topics text, the Rules for Participation in the IMI JU collaborative projects, the Rules for Submission, Evaluation and Selection of EoIs and Full Project Proposals (FPPs), the IMI IPR rules and the IMI JU model Grant Agreement (see Information Package below).

Call Identifier: IMI-JU-9-2013

Publication Date: 9 July 2013

Call status: Open for Submission of Expressions of Interest- see deadlines below.

Budget: The indicative in kind contribution from the research-based companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) will be EUR 72.25 million. The financial contribution from the European Community to the IMI JU for the support of research activities will be a maximum of EUR 63.12 million.

Restrictions for Participation: see the Rules for Participation in the IMI JU collaborative projects.

Entities eligible to receive funding: see eligibility criteria to receive funding in the Rules for Participation in the IMI JU collaborative projects.

Selection of Expressions of Interest and Full Project Proposals: see Rules for Submission, Evaluation and Selection of Expressions of Interest and Full Project Proposals.

Compliance with ethical issues: information is available on the following internet address:
http://cordis.europa.eu/fp7/ethics_en.html

Information Package: Contains the key documents required for the preparation of your Expression of Interest.

- **Topics:**
 - WEBAE – Leveraging Emerging Technologies for Pharmacovigilance
 - Developing Innovative Therapeutic Interventions Against Physical Frailty and Sarcopenia (ITI-PF&S) as a Prototype Geriatric Indication
 - Driving re-investment in R&D and Responsible Use of Antibiotics (ND4BB topic 4)
 - Clinical development of antibacterial agents for Gram-negative antibiotic resistant pathogens (ND4BB topic 5)
- **Deadline:** 9 October 2013

- **IMI-2** will help develop the next generation of cost-efficient vaccines, medicines and treatments that Europe desperately needs.
- Budget: €3.45 billion (2014 – 2024)
- Start date: January 2014



<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2013:0495:FIN:en:PDF>



- COST (European Cooperation in Science and Technology) is one of the longest-running European frameworks supporting cooperation among scientists and researchers across Europe
- Started with 19 countries, currently 35 (COST countries: 28 EU members + Bosnia and Herzegovina, F.Y.R.M., Iceland, Norway, Serbia, Switzerland, Turkey) + 4 reciprocal agreements (Australia, New Zealand, Argentina and South Africa)

COST: key features



- Building capacity by connecting high-quality scientific communities throughout Europe and worldwide;
- Providing networking opportunities for early career investigators;
- Increasing the impact of research on policy makers, regulatory bodies and national decision makers as well as the private sector.

http://www.cost.eu/about_cost



- Bottom-up science and technology networks open to researchers and stakeholders
- Four-year duration
- Minimum participation of 5 COST countries
- Provides support for networking activities carried out within COST Actions
- Funds for a range of networking tools, such as workshops, conferences, training schools, short-term scientific missions (STSMs), and dissemination activities (~100.000 € per year and action)





Scientists and researchers in COST Member Countries **can participate** in COST-funded science and technology networks - known as COST Actions - in two ways:

- Submitting a proposals for a **new COST Action**
- Joining an **existing COST Action** of their interest



- Programme managed by EAHC (Executive Agency for Health and Consumer)
- Participants: 28 MS UE, + EFTA/EEA countries (Island, Lichtenstein, Norway) (Other countries institutions only as subcontracted or collaborating partners)
- Health Public Interventions: Joint Actions (Member States Health Min.)
- European Dimension
- Objectives: Health Security, Promote Health and Health Information

http://ec.europa.eu/health/programme/policy/index_en.htm


- One of the spending programme proposals within the Multi-Annual Financial Framework 2014-2020
- The only programme exclusively dedicated to health
- Seven years duration, € 446 million in current prices
- A financial tool at the service of wider EU health policy



“Promoting good health is an integral part of the smart and inclusive growth objectives of Europe 2020”

- One of the spending programme proposals within the Multi-Annual Financial Framework 2014-2020
- The only programme exclusively dedicated to health
- Seven years duration, € 446 million in current prices
- A financial tool at the service of wider EU health policy

LA GUERNICA



www.aeromental.com

Contact details



Thank you for
your attention!

Teresa Corral

Institute of Health Carlos III

<https://ope.isciii.es>

tcorral@isciii.es